Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年5月9日，醫療保健行業的五隻股票可能會向將動量視爲交易決策關鍵標準的投資者發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一個動量指標，它比較股票在價格上漲的日子裏的走強與價格下跌的日子的走強。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數高於70時，資產通常被視爲超買。
Here's the latest list of major overbought players in this sector.
以下是該行業主要超買參與者的最新名單。
Zai Lab Limited (NASDAQ:ZLAB)
Zai Lab Limited（納斯達克：ZLAB）
- On May 8, Zai Lab posted better-than-expected quarterly results. "Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio," said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. The company's stock gained around 3% over the past month and has a 52-week high of $37.92.
- RSI Value: 72.24
- ZLAB Price Action: Shares of Zai Lab fell 0.7% to close at $16.57 on Wednesday.
- 5月8日，Zai Lab公佈了好於預期的季度業績。Zai Lab創始人、董事長兼首席執行官Samantha Du博士表示：“我們第一季度的業績表明，我們潛在的一流和一流產品組合的商業執行力強勁，並在產品線中取得進展。該公司的股票在過去一個月中上漲了約3％，創下52周高點37.92美元。
- RSI 值：72.24
- ZLAB 價格走勢：週三，Zai Lab的股價下跌0.7％，收於16.57美元。
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
塔蘇斯製藥公司（納斯達克股票代碼：TARS）
- On May 8, Tarsus Pharmaceuticals reported better-than-expected first-quarter financial results. "This was another tremendous quarter for Tarsus as we continued building a new category in eye care to serve millions of Demodex blepharitis patients with XDEMVY," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. The company's stock gained around 15% over the past five days and has a 52-week high of $40.40.
- RSI Value: 74.27
- TARS Price Action: Shares of Tarsus Pharmaceuticals fell 1.8% to close at $37.35 on Wednesday.
- 5月8日，塔蘇斯製藥公佈的第一季度財務業績好於預期。Tarsus首席執行官兼董事長Bobak Azamian醫學博士、博士表示：“對於Tarsus來說，這是又一個不錯的季度，因爲我們繼續建立新的眼科護理類別，爲數百萬患有XDEMVY的蠕形蟎瞼炎患者提供服務。”該公司的股票在過去五天中上漲了約15％，創下52周高點40.40美元。
- RSI 值：74.27
- TARS價格走勢：週三，塔蘇斯製藥公司股價下跌1.8％，收於37.35美元。
Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Edgewise Therapeutics, Inc.（納斯達克股票代碼：EWTX）
- On May 7, Edgewise Therapeutics named Arlene Morris to its Board of Directors. The company's stock gained around 29% over the past month and has a 52-week high of $21.60.
- RSI Value: 74.25
- EWTX Price Action: Shares of Edgewise Therapeutics fell 1.6% to close at $20.89 on Wednesday.
- 5月7日，Edgewise Therapeutics任命阿琳·莫里斯爲董事會成員。該公司的股票在過去一個月中上漲了約29％，創下52周高點21.60美元。
- RSI 值：74.25
- EWTX價格走勢：週三，Edgewise Therapeutics的股價下跌1.6％，收於20.89美元。
GSK plc (NYSE:GSK)
葛蘭素史克公司（紐約證券交易所代碼：GSK）
- On May 1, GSK reported better-than-expected first-quarter results and raised its 2024 core operating profit guidance. GSK expects 2024 adjusted EPS growth of 8% to 10%, up from the 6%-9% growth previously forecast. It expects 2024 sales to grow in the upper end of its 5% to 7% forecast range. The company's stock jumped around 10% over the past month and has a 52-week high is $44.33.
- RSI Value: 72.85
- GSK Price Action: Shares of GSK fell 0.02% to close at $44.14 on Wednesday.
- 5月1日，葛蘭素史克公佈的第一季度業績好於預期，並上調了2024年核心營業利潤預期。葛蘭素史克預計，2024年調整後的每股收益將增長8％至10％，高於先前預測的6％-9％的增長。該公司預計，2024年的銷售額將在其5％至7％的預測區間內增長。該公司的股票在過去一個月中上漲了約10％，創52周高點爲44.33美元。
- RSI 值：72.85
- 葛蘭素史克價格走勢：葛蘭素史克股價下跌0.02％，週三收於44.14美元。
AstraZeneca PLC (NASDAQ:AZN)
阿斯利康公司（納斯達克股票代碼：AZN）
- AstraZeneca has declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an "excess of updated vaccines." The company's stock jumped around 13% over the past month and has a 52-week high of $77.16.
- RSI Value: 75.58
- AZN Price Action: Shares of AstraZeneca climbed 0.9% to close at $76.97 on Wednesday.
- 由於 “更新後的疫苗過多”，阿斯利康宣佈在全球範圍內停止其 COVID-19 疫苗Vaxzevria。該公司的股票在過去一個月中上漲了約13％，創下52周高點77.16美元。
- RSI 值：75.58
- AZN價格走勢：週三，阿斯利康股價上漲0.9％，收於76.97美元。
Read More: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday
閱讀更多：進入週四，Roblox、Beyond Meat和3只值得關注的股票
譯文內容由第三人軟體翻譯。